Abbvie said on Friday it would record a charge of about $3.5 billion related to its experimental schizophrenia drug, ...

IGM Biosciences (NASDAQ:IGMS) is slashing its workforce by 73% and discontinuing development of two of its lead drug ...

Early treatment escalation to biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) following methotrexate (MTX) failure in new-onset rheumatoid arthritis (RA) does not ...

There is a bidirectional association between rheumatoid arthritis (RA ... muscle and bone diseases. Various treatments are available. Non-pharmacological treatment includes physical therapy ...

IGM Biosciences announced the discontinuation of imvotamab and IGM-2644 for autoimmune and inflammatory diseases, including ...

Abbvie said on Friday it would record a charge of about $3.5 billion related to its experimental schizophrenia drug, ...

Study to determine which treatments best for which inflammatory arthritis patients should result in patients being better ...

GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase I for Rheumatoid Arthritis.

ORYN-1001 is under clinical development by Oryn Therapeutics and currently in Phase I for Rheumatoid Arthritis.

OMNY Health, the leading healthcare ecosystem for compliant real-world data insights at scale, and Scipher Medicine, which ...